Risk factors
BioXcel Therapeutics (BTAI) risk factors
Item 1A of every BioXcel Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors82 risks10 new10 dropped16 reworded
BioXcel Therapeutics faces critical funding constraints and ongoing FDA hurdles for expanding IGALMI and BXCL501 indications. New trade policies introduce tariff risks on imports, while Nasdaq listing compliance remains a persistent concern.
Filed Mar 27, 2026 - FY2024 10-K risk factors82 risks
BioXcel faces severe going concern doubts, relying on $29.8 million in cash and $14.0 million in March 2025 proceeds to fund operations into the third quarter of 2025.
Filed Mar 28, 2025